Evidence buyer path

For data and research buyers such as biotech, pharma, CRO, academic, DeSci, payer, and other teams evaluating governed real-world evidence or data access.

Provider network is a separate lane
  1. Step 11
    Evidence loop
  2. Step 22
    Methodology brief
  3. Step 33
    Data quality
  4. Step 44
    Governance
  5. Step 55
    Data requests
  6. Step 66
    Inquiry
Step 1 - Evidence loop

From member-side data to evidence-buyer diligence.

Evidence buyers include biotech, pharma, CROs, academic researchers, DeSci groups, payers, and other teams evaluating governed real-world evidence. Start here before reviewing methodology, data quality, governance, or data-request scope.

Evidence loop

The sequence buyers should inspect.

The loop is intentionally framed as a diligence path. Synthetic and proxy support help explain the product shape; production evidence still requires the appropriate human reviews.

Step 1

Member-consented inputs

Protocol logs, lab panels, wearable context, and phenotype reports enter the review path with consent and use boundaries.

Step 2

Normalized multimodal dataset

Inputs are organized into a structured RWE shape that can be reviewed for completeness, gaps, and cohort fit.

Step 3

Synthetic-control analysis

The DS-CDT demo shows how synthetic controls, biomarker volatility, and de-identified assets can be represented in product code.

Step 4

Governed partner request

Any production access remains scoped by DUA, consent audit, de-identification review, and partner-specific requirements.

Buyer questions

What this helps a buyer evaluate.

These use cases are framed as review paths, not clinical, legal, regulatory, or production readiness claims.

Synthetic-control exploration

Review how matched comparator logic could support external-control discussions after cohort, governance, and validation questions are answered.

Signal review across protocols

Inspect how protocol logs, wearable windows, and lab panels can be organized for research questions without presenting synthetic data as clinical proof.

Data-pack scoping

Move from evidence fit to a scoped request that defines cohort needs, refresh cadence, review boundaries, and access constraints.

Next step

Next, review the methodology.

The methodology brief explains the DS-CDT evidence approach in buyer language before your team evaluates data quality, governance, and request scope.

Evidence Buyer Path | LifePrint